BioNTech (NASDAQ:BNTX) PT Lowered to $122.00

BioNTech (NASDAQ:BNTX) had its price target cut by analysts at BMO Capital Markets from $123.00 to $122.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 33.58% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $107.00 target price on shares of BioNTech in a research note on Wednesday, April 17th. The Goldman Sachs Group lowered their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. UBS Group lowered their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a report on Wednesday, March 27th. JPMorgan Chase & Co. dropped their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, BioNTech currently has an average rating of “Hold” and a consensus price target of $120.30.

BioNTech Trading Down 2.2 %

BNTX stock traded down $2.02 during trading on Tuesday, reaching $91.33. 221,523 shares of the stock traded hands, compared to its average volume of 654,398. BioNTech has a 52-week low of $85.21 and a 52-week high of $125.83. The business’s 50 day moving average price is $90.53 and its 200-day moving average price is $95.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The firm has a market capitalization of $21.71 billion, a PE ratio of 22.28 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. As a group, sell-side analysts forecast that BioNTech will post -1.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Cambridge Investment Research Advisors Inc. grew its stake in BioNTech by 3.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares in the last quarter. Raymond James & Associates raised its position in shares of BioNTech by 5.6% in the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock valued at $606,000 after acquiring an additional 298 shares during the period. Mackenzie Financial Corp lifted its position in BioNTech by 86.5% in the 3rd quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock valued at $558,000 after acquiring an additional 2,380 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of BioNTech by 9.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 81,103 shares of the company’s stock valued at $8,811,000 after buying an additional 6,682 shares during the last quarter. Finally, Flossbach Von Storch AG increased its holdings in shares of BioNTech by 2.1% during the 3rd quarter. Flossbach Von Storch AG now owns 3,513,215 shares of the company’s stock worth $381,676,000 after acquiring an additional 71,468 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.